


**DESIGN, SYNTHESIS, PHARMACOLOGICAL EVALUATION AND
MOLECULAR MODELLING STUDIES OF N-SUBSTITUTED PIPERIDINE-3-
CARBOXYLIC ACID DERIVATIVES AS POTENTIAL ANTICONVULSANTS**



**THESIS SUBMITTED FOR THE AWARD OF THE DEGREE
OF
Doctor of Philosophy**

Submitted By

Ankit Seth

M. Pharm

Supervisor

Dr. S. K. Shrivastava

Professor

**DEPARTMENT OF PHARMACEUTICAL ENGINEERING & TECHNOLOGY
INDIAN INSTITUTE OF TECHNOLOGY
(BANARAS HINDU UNIVERSITY)
VARANASI-221 005 (U.P.), INDIA**

Enrolment No. 323893

Roll No. 10621EN002

ABSTRACT:

Epilepsy is a neurological disorder with a focal origin in the brain and is characterized by paroxysmal cerebral dysrhythmia, recurrent seizures, and disturbance of consciousness. Despite the availability of numerous antiepileptic agents in the drug market, nearly 20–30% of the 70 million epilepsy patients worldwide have insufficient control over seizures and are resistant to the currently available pharmacotherapy. Moreover, the poor tolerability and reported side effects of the antiepileptic drugs have affected the quality of life of the epilepsy patients. Thus, to address these massive challenges, development of novel antiepileptic drugs with improved efficacy, considerable tolerability, and lower toxicity is a paramount necessity.

GABA is the main inhibitory neurotransmitter in the brain of mammals that plays a considerable role in the pathogenesis of epilepsy. Low brain GABA concentration and diminution in GABA-ergic neurotransmission have been observed in a range of epileptic syndromes. The transport of GABA from synaptic cleft to the glial cells as well as presynaptic neurons is mediated by GABA transporters (GATs), which results in the termination of GABA-ergic neurotransmission. GATs are the member of sodium symporters, which belong to solute carrier 6 (SLC6) transporter gene family in humans and mediates neurotransmitter transport. Elevation in GABA concentration within the synaptic cleft is proved to be advantageous in the management of epilepsy. One such strategy for the up-regulation of GABA would be the blockade of specific subtypes of GATs, which are responsible for neuronal and glial uptake of GABA from the synaptic cleft. Inhibitors of GABA uptake are of utmost significance as regulators of neurotransmitter levels that increase the duration of inhibitory postsynaptic potentials to elicit antiepileptic activity.

The discovery of piperidine-3-carboxylic acid (nipecotic acid) as a high-affinity substrate for GABA transporter remarkably added new prospects of targeting GABA uptake systems. It has been reported to exhibit significant *in vitro* activity as an inhibitor of uptake of GABA into neuronal and glial cells. However, it is unable to cross blood brain barrier (BBB) owing to its zwitterionic and polar nature. The synthetic versatility of piperidine-3-carboxylic acid led to the discovery of lipophilic derivatives which have been explored as useful inhibitors of GABA uptake. Despite the synthesis of these diverse derivatives, BBB permeation remains the key bottleneck for brain drug delivery. The single marketed derivative of the piperidine-3-carboxylic acid, i.e., tiagabine is a GAT-1 selective GABA

uptake inhibitor with considerable antiepileptic potential. Reported GABA uptake inhibition triggered by tiagabine has been attributed to the presence of GABA mimetic moiety in the form of piperidine-3-carboxylic acid and a lipophilic di-aromatic region connected by a linker. Tiagabine is effectively used as supportive therapy for the management of complex partial seizures in epilepsy patients. However, its long-term use is associated with adverse effects like asthenia, tremor, concentration difficulties, lethargy, nervousness, and depression. Therefore, scope to develop novel compounds with improved BBB permeation and lesser side effects is still a challenge for medicinal chemists in the discovery of new drugs to treat epilepsy.

Compounds inhibiting GABA uptake have been extensively used as a pharmacological tool to explicate several aspects of neurological processes which involve GABA. Nipecotic acid, which is a reported GABA uptake inhibitor, has gained considerable attention for the design and synthesis of lipophilic analogs with marked antiepileptic activity. Based on the SAR of the reported N-substituted derivatives of nipecotic acid endowed with antiepileptic potential and taking cognizance of known GABA uptake inhibitors especially tiagabine as a benchmark, an attempt was made to synthesize two series of novel derivatives of nipecotic acid.

In search of new chemical entities (NCE's) for the mitigation of epilepsy, naphthyl ketones are considered to be attractive scaffolds owing to their lipophilic nature and reported applications in the design and synthesis of some derivatives with marked antiepileptic activity. With a rationale of synthesizing novel analogs which can effectively permeate through the BBB, a lipophilic scaffold such as naphthyl ketone has been introduced at the ring nitrogen of nipecotic acid, thereby utilizing the concept of molecular hybridization to obtain novel hybrids in the first series. Herein, the substituted naphthalene nucleus at the second position was hybridized with nipecotic acid with an aim to assist the molecule in permeating through the BBB owing to their increased lipophilic nature. A methylene bridge connecting the parent scaffolds afforded the necessary flexibility to the overall structure. The synthesized compounds were evaluated in subcutaneous pentylenetetrazol (sc-PTZ), Pilocarpine and Methyl-6,7-dimethoxy-4-ethyl- β -carboline-3-carboxylate (DMCM) induced seizure models to obtain potential leads with antiepileptic activity. The potential hybrids attained after the *in vivo* screening were further evaluated for their BBB permeability by an *in vitro* parallel artificial membrane permeability BBB assay

(PAMPA-BBB). Neurological side effects of antiepileptic drugs have been reported in several literatures. The effects of the leads on motor coordination were evaluated by rota-rod test on rodents. The effects of the active compounds on cell viability was determined in neuroblastoma cell line (SH-SY5Y) by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Also, the safety profile of the most promising compound and the standard drug (tiagabine) was evaluated with respect to various hematological, hepatic, and renal parameters. Further the homology modelling, *in silico* docking studies and molecular dynamics simulation of the most active compound were performed at the GAT1 active site. QikProp module of Schrödinger Maestro 10.5.014 Release 2016-1 was used to predict the “drug likeliness” of the active compounds (**4S1a**, **4S1b** and **4S1i**).

Schiff bases are also reported to be attractive scaffolds in the exploration of NCEs as antiepileptics, owing to their lipophilic nature and reported applications in the design and synthesis of derivatives with marked antiepileptic activity. Based on the philosophy of bio-isosterism, we have hypothesized to construct a new molecular framework by synthesizing another series of novel Schiff bases of 1-(2-aminoethyl)piperidine-3-carboxylic acid as potential anticonvulsants, with the same objective of increasing lipophilicity and BBB permeability with respect to parent scaffold. In this series, the synthesized compounds have been initially screened for their ability to permeate the blood–brain barrier (BBB) by an *in vitro* parallel artificial membrane permeability assay (PAMPA-BBB). PAMPA-BBB was performed in the first step owing ethical considerations and to limit the animal experimentation. The potential leads exhibiting *in vitro* BBB permeability (**5S2d**, **5S2f**, **5S2j**, **5S2l**, **5S2m**, **5S2n**, **5S2w**, **5S2x** and **5S2y**) were further evaluated for anticonvulsant activity in sc-PTZ and DMCM induced seizure models. Rota-rod test on rodents, MTT assay and safety profiling was performed with the same objective as in the first series. The leads (**5S2d**, **5S2w**, and **5S2y**) were then subjected to molecular docking on the same homology modeled protein to identify and compare the complementary interactions of the compounds with the amino acid residues of the active pocket. The binding modes of the most active compound (**5S2w**) were further probed using molecular dynamics simulation at the GAT1.

Amongst the synthesized derivatives of series 1, compounds **3S1a**, **3S1b**, **3S1i**, **4S1a**, **4S1b**, and **4S1i** exhibited increased latency of seizures against subcutaneous

pentylentetrazole (scPTZ) induced seizures in mice. Derivatives **4S1a**, **4S1b**, **4S1i** were more effective compared to the ester counterparts **3S1a**, **3S1b** and **3S1i** placing the importance of the presence of free carboxyl group in the centre. Predicted values for **QPlogBB** and **CNS activity**, indicates that the selected compounds were found to be active for CNS and might be permeable across BBB. The *in silico* results were further supported by the findings of *in vitro* parallel artificial BBB permeability assay which suggested that the evaluated derivatives exhibited considerable permeability to cross BBB. The compound **4i** was comparatively more permeable ($Pe= 8.89$) across BBB than the standard tiagabine ($Pe= 7.86$). *In silico* studies proved the consensual interactions of compound **4i** with the active binding pocket. From Series 2, compounds **5S2d**, **5S2f**, **5S2j**, **5S2l**, **5S2m**, **5S2n**, **5S2w**, **5S2x** and **5S2y** elicited considerable *in vitro* permeability across BBB. The outcome of the *in vivo* models suggested that **5S2d**, **5S2w**, and **5S2y** were most potent amongst the synthesized compounds. Leads from both the series (**4S1a**, **4S1b**, **4S1i**, **5S2d**, **5S2w**, and **5S2y**) did not cause any alteration in “fall-off” time on rota rod apparatus as compared to the control, tiagabine and standard (diazepam) indicating their inability to induce any observable signs of impairment in muscle co-ordination. The MTT assay revealed that the test compounds (**4S1a**, **4S1b**, **4S1i**, **5S2d**, **5S2w**, and **5S2y**) were not found to alter the cell viability considerably, thus corresponds to the insignificant cell death in the concentrations of the test compounds ranging from 1 μ M to 80 μ M. The results of the evaluation of various haematological and biochemical parameters revealed the safety of the most promising compounds (**4S1i** & **5S2w**) from both the series at an equimolar dose relative to 10 mg/kg tiagabine. Based on the outcome of the *in silico* studies, we can reasonably infer that the potential derivatives exhibits consensual interactions with the active binding pocket of GAT 1 similar to tiagabine. All together the efficacy and safety of the potential leads justifies the rationale behind the study and provide a valuable insight towards the development and optimization more promising compounds with superior anticonvulsant effects.

*Dedicated to the Almighty,
My Family, Teachers
and Friends*

Acknowledgements

*Prima facie, I am grateful to the God for giving me good health and wellbeing that were necessary to complete this research work. I bow at the lotus feet of Bharat Ratna **Pandit Madan Mohan Malaviyaji**, founder of the Banaras Hindu University.*

*I would like to express my gratitude to my mentor, guide and **guardian Prof. Sushant Kumar Shrivastava**, for his support, patience, guidance, motivation and encouragement throughout my Ph.D. Thank you for believing in me and giving me ample space to grow by myself. Your technical and editorial advice was essential to the completion of this dissertation and has taught me innumerable lessons and insights on the workings of academic research and in general. I am indebted to him for his appreciation for success, backing and support in failures, which ultimately made me keen to tackle any obstructions occurring during the research work. Without his supervision and constant help, this dissertation would not have been possible.*

*I also take this opportunity to express my deepest gratitude **Prof. Sanjay Singh**, Head, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi for allowing me to use the Departmental facilities for carrying out my research work.*

*I am grateful to, **Prof. S.K. Singh** and **Prof. B. Mishra**, Former Heads, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi for their constant inspiration, valuable suggestions and help which have led to the successful completion of this work.*

*I wish to express my heartiest gratitude to **Dr. A.K. Srivastava**, **Prof. Hemalatha S.**, **Prof. K. Sairam**, **Dr. Senthil Raja A.**, **Dr. M.S. Muthu**, **Dr. A.N. Sahu**, **Dr. S.K. Mishra**, **Dr. R. Chawla**, **Dr. P.K. Nayak**, **Dr. V.K. Tiwari**, **Dr. S.K. Jain**, and **Dr. A. Agrawal** for their constant help and support.*

*I owe a warm thanks to **Dr. Gyan Prakash Modi** for helping me in carrying out the homology modeling of GAT-1, which is a very crucial part of my thesis.*

*I owe my gratitude to all my respected **RPC members** for their encouragement and insightful comments leading me to the completion of the research work.*

*I pay my sincere thanks to **Mr. Nandlal, Mr. Madan, Mr. Upadhya, Mr. Sanjeev, Mr. Yashwant, Mr. Jameel, Mr. Pathak, Mr. Arun, Mr. Gopal, Mrs. Saroj Kumari, Mrs. Archana Singh, Ms. Shyamli Ghoshal** and other non-teaching staff of the Department for their timely assistance and co-operation during my Ph.D. tenure.*

*I have been blessed with a friendly and cheerful group of fellow students **Mr. Piyush Sharma, Dr. Anupam Banerjee and Dr. Gireesh kumar Singh**, who were always willing to help and give their best suggestions as well as moral support. I cannot forget the efforts made by them in preparation and submission of the thesis.*

*I would particularly like to acknowledge the contribution of my batch-mates **Dr. Nagendra, Dr. Dileep, Dr. Debapriya, Dr. Sanjay, Anshul, Ranga and Gopal**. It is not sufficient to express my gratitude with only a few words. They have always been there to motivate me during the hour of hardship and helped me unconditionally throughout Ph.D. tenure.*

*I am indeed thankful to have the company of friendly lab mates **Mr. Pavan, Mr. Prabhash, Mr. Avanish, Mr. Tanmaya, Mrs. Priyanka, Dr. Manish, Mr. Digambar, Mrs. Mousami, Ms. Poorvi & Mr. Sombir** who were ever ready to provide me with all possible help. They created a happy working environment and foster camaraderie within the laboratory.*

*Amongst my juniors, I would like to thank **Mukesh, Gopi, Devendra, Sathish and Gunjan** for their alacrity and support during the tenure.*

*I also acknowledge the warm support extended to me by **Dr. Manish Kumar, Dr. Damiki Laloo, Dr. S.K. Prasad, Mr. Ravi B. Singh and Dr. Aditya Singh**. They made my stay at Varanasi a very pleasant and memorable one.*

*I would also like to express my thanks to my ever supportive seniors: **Dr. Nirupam Das, Dr. Meenakshi Dhanawat, Dr. Saurabh K. Sinha, Dr. Chhanda C.***

Danta, Dr. Rahul Tripathi and Dr. Achint Jain who were always there with a helping attitude whenever I was in need.

A special thanks to my family. Words cannot express how grateful I am to all my family members for all of the sacrifices that they made on my behalf and continuous support they provided to me. Most importantly, none of this would have been possible without the love and patience of my **parents and wife**. They have been a constant source of love, moral support and strength all these years. I owe this achievement to them.

Last but not the least, I pray **God** for the **animals** who were mortified for the cause of research and advancement of knowledge. May their souls rest in peace.

Date:

Place: Varanasi

(Ankit Seth)

INDEX

CONTENTS	Page No.
List of Abbreviations	i-ii
List of Figures	iii-iv
List of Tables	v
Preface	vi-vii
CHAPTER-1 INTRODUCTION	1-13
1.1. Drug Design, Discovery and Development	1
1.2. Epilepsy: An Overview	3
1.3. GABA Hypothesis & Epilepsy	8
1.3.1. GABA Synthesis and Metabolism	9
1.3.2. GABA Receptors	9
1.3.3. GABA Transporters	10
1.4. Piperidine 3-Carboxylic Acid (Nipecotic Acid)	11
CHAPTER-2 REVIEW OF LITERATURE	14-26
2.1. Nipecotic Acid: An <i>In Vitro</i> GABA Reuptake Inhibitor	14
2.2. Piperidine-3-Carboxylic Acid Derivatives as Anticonvulsants	15
2.3. Naphthalene Derivatives as Anticonvulsants	23
CHAPTER-3 RATIONALE, OBJECTIVE AND PLAN OF WORK	27-29
3.1. Rationale and Objective	27
3.2. Plan of Work	28
CHAPTER-4 EXPERIMENTAL	30-43
4.1. Chemistry	30
4.1.1. Chemicals and Reagents	30
4.1.2. Series 1	30
4.1.2.1. Method of Preparation	30
4.1.2.2. Reaction Mechanism for Series 1	31
4.1.3. Series 2	32
4.1.3.1. Method of Preparation	32
4.1.3.2. Reaction Mechanism for Series 2	34
4.1.4. Characterisation of Synthesised Compounds	34
4.1.4.1. Physicochemical Characterisation	35
4.1.4.2. Spectral Characterisation and Elemental Analysis	36
4.2. Biological Activity of Series 1	37
4.2.1. Animals	37
4.2.2. Drug Administration	37
4.2.3. Evaluation of <i>In Vivo</i> Anti-Convulsant Activity	37

CONTENTS	Page No.
4.2.3.1. sc-PTZ Induced Seizures in Mice	37
4.2.3.2. Pilocarpine Induced Seizures in Mice	38
4.2.3.3. DMCM Induced Seizures in Mice	38
4.2.4. Rota-rod Performance Test in Mice	38
4.2.5. MTT Assay on Neuroblastoma Cell Line (SH-SY5Y)	39
4.2.6. In Vitro Parallel Artificial Membrane BBB Permeability Assay (PAMPA)	39
4.3. Biological Activity of Series 2	40
4.4. Statistical analysis	40
4.5. Computational Studies	40
4.5.1. Homology Modelling of GAT-1	40
4.5.2. <i>In Silico</i> Docking	41
4.5.3. Molecular Dynamics (MD)	42
4.4.2.1. MD Simulation Protocol for Compound 4i	42
4.4.2.1. MD Simulation Protocol for Compound 5w	42
4.5.4. Prediction of drug likeliness and <i>in silico</i> ADME	43
CHAPTER-5 RESULTS AND DISCUSSION	44-92
5.A. Synthesis of Acetonaphthones Tethered Piperidine-3-Carboxylic Acid Derivatives. [series 1]	44-67
5.A.1. Chemistry	44
5.A.1.1. Physicochemical Characterisation	44
5.A.1.2. Spectral Characterisation and Elemental Analysis	45
5.A.2. Biological Activity	51
5.A.2.1. Evaluation of Anticonvulsant Activity	51
5.A.2.2. Rota-rod Performance Test in Mice	54
5.A.2.3. Cell viability and neurotoxicity (MTT Assay)	55
5.A.2.4. <i>In Vitro</i> PAMPA-BBB Assay	56
5.A.3. Computational Studies	80
5.A.3.1. Homology modeling of GAT-1	58
5.A.3.2. <i>In Silico</i> Docking	60
5.A.3.3. <i>In Silico</i> Molecular Dynamics	63
5.A.3.4. Estimation of "Drug-Like" Properties	66
5.B. 5,6-diphenyl-1,2,4-triazine-3(2 <i>H</i>)-ones bearing five-member (1,3,4 oxadiazole/thiadiazole, 1,2,4-triazole) heterocyclic moieties [Series 2]	68-92
5.B.1. Chemistry	68
5.B.1.1. Physicochemical Characterisation	68

CONTENTS	Page No.
5.B.1.2. Spectral Characterisation and Elemental Analysis	70
5.B.2. Biological Activity	79
5.B.2.1. <i>In Vitro</i> PAMPA-BBB Assay	79
5.B.2.2. Evaluation of Anticonvulsant Activity	81
5.B.2.3. Rota-rod Performance Test in Mice	84
5.B.2.4. . Cell viability and neurotoxicity (MTT Assay)	85
5.B.3. Computational Studies	85
5.B.3.1. Homology modeling of GAT-1	85
5.B.3.2. <i>In Silico</i> Docking	86
5.B.3.3. <i>In Silico</i> Molecular Dynamics	89
5.B.3.4. Estimation of “Drug-Like” Properties	91
CHAPTER-6 SUMMARY AND CONCLUSION	93-96
CHAPTER-7 REFERENCES	97-113
CHAPTER-8 APPENDIX	114-125
8.1. ¹ H and ¹³ C Spectra of Representative Compounds from Series 1	114
8.2. ¹ H and ¹³ C Spectra of Representative Compounds from Series 2	120
LIST OF RESEARCH PAPERS AND PRESENTATIONS	
REPRINTS OF PUBLISHED RESEARCH PAPERS	

<p>% – Percentage</p> <p>°C – Degree centigrade</p> <p>µl – Microlitre</p> <p>µM – Micromolar</p> <p>ALP – Alkaline phosphatase</p> <p>ALT – Alanine transaminase</p> <p>ANOVA – Analysis of variance</p> <p>AST – Aspartate transaminase</p> <p>ATP – Adenosine triphosphate</p> <p>BUN – Blood urea nitrogen</p> <p>CADD – Computer aided drug design</p> <p>CDCl₃ – Deuterated chloroform</p> <p>cm – Centimeter</p> <p>CNS – Central nervous system</p> <p>CoMFA – Comparative molecular field analysis</p> <p>CoMSIA – Comparative molecular similarity indices analysis</p> <p>DMCM – Methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate</p> <p>ED₅₀ – Median effective dose</p> <p>FDA – Food and drug administration</p> <p>FTIR – Fourier transform infrared spectroscopy</p> <p>g – Gram(s)</p> <p>GABA – γ-aminobutyric acid</p> <p>GAT – GABA transporters</p> <p>h – Hour</p> <p>i.p. – Intraperitoneal</p> <p>IC₅₀ – Half maximal inhibitory concentration</p>	<p>TLC – Thin layer chromatography</p> <p>TMS – Tetramethylsilane</p> <p>UV – Ultra violet</p> <p>XRD – X-ray diffraction</p>
--	--

<p>Kg – Kilogram</p> <p>LBDD – Ligand based drug design</p> <p>m.p. – Melting point</p> <p>MD – Molecular dynamics</p> <p>MES – Maximal electroshock</p> <p>MET – Metrazole</p> <p>MTT – 3-(4,5-Dimethylthiazol-2-yl)- 2,5-Diphenyltetrazolium Bromide</p> <p>mg – Milligram</p> <p>min – Minutes</p> <p>ml – Milliliter</p> <p>mm – Millimeter</p> <p>mmol – Millimole</p> <p>Mol. Eq. – Molar equivalent</p> <p>NCE – New chemical entity</p> <p>NMDA – N-methyl-D-aspartate</p> <p>NMR – Nuclear magnetic resonance</p> <p>ns – Nanosecond</p> <p>OECD – Organization for economic co-operation and development</p> <p>OPLS – Optimised potentials for liquid simulations</p> <p>P – Partition coefficient</p> <p>PAMPA – Parallel artificial membrane permeability assay</p> <p>p.o. – Per oral</p> <p>PDB – Protein data bank</p> <p>ps – Picosecond</p> <p>PTZ</p> <p>QSAR – Quantitative structure-activity relationship</p>	
--	--

<p>R_f – Retention factor</p> <p>RMSD – Root mean square deviations</p> <p>rpm – Revolutions per minute</p> <p>s – Seconds</p> <p>SBDD – Structure-based drug design</p> <p>sc – Subcutaneous</p> <p>scPTZ – Subcutaneous pentylenetetrazole</p> <p>SD – Standard deviation</p> <p>SBDD – Structure based drug design</p>	
--	--

CONTENTS	PAGE NO.
List of Abbreviations	i
List of Figures	ii-iii
List of Tables	iv
Preface	v-vi
1. INTRODUCTION	
1.1. Drug Design, Discovery, and Development	1
1.2. Epilepsy: An Overview	4
1.3. GABA Hypothesis & Epilepsy	10
1.3.1. GABA Synthesis and Metabolism	11
1.3.2. GABA Receptors.....	12
1.3.3. GABA Transporters	13
1.4. Piperidine 3-Carboxylic Acid (Nipecotic Acid)	15
2. REVIEW OF LITERATURE	
2.1. Nipecotic Acid: An <i>In Vitro</i> GABA Reuptake Inhibitor	19
2.2. Piperidine-3-Carboxylic Acid Derivatives as Anticonvulsants	20
2.3. Napthalene Derivatives as Anticonvulsants	30
3. RATIONAL, OBJECTIVE AND PLAN OF WORK	
3.1. Rationale & Objective	35
3.2. Plan of Work	36
3.2.1. Synthesis	36
3.2.2. Characterization of the Synthesized Compounds (Series 1 and 2)	37
3.2.3. Biological Evaluation of Series 1	37
3.2.4. Biological Evaluation of Series 2.....	37
3.2.5. Computational Studies of the Selected Leads from Series 1 & 2	38
4. EXPERIMENTAL	
4.1. Chemistry	39
4.1.1. Chemicals and Reagents	39
4.1.2. Series 1	39
4.1.2.1. <i>Method of Preparation</i>	39
4.1.2.2. <i>Reaction Mechanism for Series 1</i>	41
4.1.3. Series 2	41
4.1.3.1. <i>Method of Preparation</i>	41
4.1.3.2. <i>Reaction Mechanism for Series 2</i>	44

4.1.4. Characterization	44
4.1.4.1. <i>Physicochemical Characterization</i>	45
4.1.4.2. <i>Spectral Characterization and Elemental Analysis</i>	46
4.2. Biological Activity of Series 1	47
4.2.1. Animals	47
4.2.2. Drug Administration	48
4.2.3. <i>In Vivo</i> Anti-convulsant Activity	48
4.2.3.1. <i>sc-PTZ Induced Seizures in Mice</i>	48
4.2.3.2. <i>Pilocarpine Induced Seizures in Mice</i>	48
4.2.3.3. <i>DMCM Induced Seizures in Mice</i>	49
4.2.4. Rota-rod Performance Test in Mice	49
4.2.5. MTT Assay on Neuroblastoma Cell Line (SH-SY5Y)	49
4.2.6. Repeated dose toxicity studies:	50
4.2.7. <i>In Vitro</i> PAMPA-BBB Assay	51
4.3. Biological Activity of Series 2	51
4.4. Statistical Analysis	52
4.5. Computational Studies	52
4.5.1. Homology Modelling of GAT-1	52
4.5.2. Molecular Docking Studies	53
4.5.3. Molecular Dynamics (MD) Simulations	54
4.5.4. Prediction of drug likeliness and <i>in silico</i> ADME properties	54
5. RESULTS AND DISCUSSION	
5A. SERIES 1	56
5.A.1. Chemistry	56
5.A.1.1. Physicochemical Characterization	56
5.A.1.2. Spectral Characterization and Elemental Analysis	57
5.A.2. Biological Activity	65
5.A.2.1. <i>In Vivo</i> Anti-convulsant Activity	65
5.A.2.1.1. <i>sc-PTZ Induced Seizures in Mice</i>	65
5.A.2.1.2. <i>Pilocarpine-induced seizures in mice</i>	67
5.A.2.1.3. <i>DMCM induced seizures in mice</i>	68
5.A.2.2. Rota-rod Performance Test in Mice	69
5.A.2.3. Cell viability and neurotoxicity (MTT Assay)	69
5.A.2.4. Repeated dose toxicity studies	70

5.A.2.5. <i>In Vitro</i> PAMPA-BBB Assay	73
5.A.3. Computational Studies	74
5.A.3.1. Homology modeling of GAT-1	74
5.A.3.3. Molecular Dynamics	81
5.A.3.4. Estimation of “Drug-Like” Properties	84
5.B. SERIES 2	86
5.B.1. Chemistry	86
5.B.1.1. Physicochemical Characterization	86
5.B.1.2. Spectral Characterization and Elemental Analysis	88
5.B.2. Biological Activity	100
5.B.2.1. <i>In vitro</i> PAMPA-BBB assay	100
5.B.2.2. <i>In Vivo</i> Anti-convulsant Activity	102
5.B.2.2.1. <i>sc-PTZ Induced Seizures in Mice</i>	102
5.B.2.2.2. <i>DMCM Induced Seizures in Mice</i>	103
5.B.2.3. Rota-rod Performance Test in Mice	104
5.B.2.2. Cell viability and neurotoxicity (MTT Assay)	105
5.B.2.3. Repeated dose toxicity studies	105
5.B.3. Computational Studies	107
5.B.3.1. Homology modeling of GAT-1	107
5.B.3.2. Molecular Docking Studies	107
5.B.3.3. Molecular Dynamics	112
5.B.3.4. Estimation of “Drug-Like” Properties	114
6. SUMMARY AND CONCLUSION	116
7. REFERENCES	121
8. APPENDIX	140

Fig. No.	Figure Captions	Page No.
1.1	Synthesis & metabolism of GABA	11
1.2	Schematic representation of synthesis, storage, release, transport and metabolism of GABA.	12
1.3	Derivatives of nipecotic acid with reported GABA transport inhibition and anti-epileptic activity	16
3.1	The design strategy for the proposed compounds under Series 1 and Series 2 .	36
4.1	Possible mechanism of reaction for the synthesis of compounds 3S1a-3S1i & 4S1a-4S1i .	41
4.2	Possible mechanism of reaction for the synthesis of compounds 5S2a-5S2y	44
5.1	Conversion of MTT to formazan in the presence of mitochondrial dehydrogenase	70
5.2	Sequence alignment between GAT-1 and drosophila melanogaster dopamine transporter. Identical residues are colored in red, while similar residues are colored in yellow.	76
5.3	Ramachandran plot of the GAT-1. 3-dimensional model showing the dihedral angles of the amino acids	76
5.4	Docked pose of the tiagabine on homology modeled protein structure of GAT-1 GABA transporter. Ribbon representation of protein showing active site binding interaction of tiagabine (ball & stick model)	79
5.5	Docked pose of the 4S1a on modeled protein structure of GAT-1 GABA transporter. Ribbon representation of protein showing active site binding interaction of 4S1a (ball & stick model).	79
5.6	Docked pose of the 4S1b on modeled protein structure of GAT-1 GABA transporter. Ribbon representation of protein showing active site binding interaction of 4S1b (ball & stick model).ule	80
5.7	Docked pose of the 4S1i on modeled protein structure of GAT-1 GABA transporter. Ribbon representation of protein showing active site binding interaction of 4S1i (ball & stick model).	80
5.8	Protein RMSD (Left Y-Axis) and ligand RMSD (Right Y-Axis) values in Å with time in nanoseconds (X-Axis).	82
5.9	Protein RMSF (Left side) and ligand RMSF (Right side) values in Å with time in nanoseconds.	82
5.10	The detailed atomic interactions of ligand 4S1i with the key active amino acid residues.	83
5.11	Stacked bar charts of protein interactions with ligand 4S1i as monitored throughout the MD simulation.	83
5.12	3D Ribbon structure representation of docking conformation of the	109

	tiagabine in the hydrophobic pocket of homology modelled protein structure of GAT-1 GABA transporter.	
5.13	3D Ribbon structure representation of docking conformation of the compound 5S2d in the hydrophobic pocket of homology modelled protein structure of GAT-1 GABA transporter.	109
5.14	3D Ribbon structure representation of docking conformation of the compound 5S2w in the hydrophobic pocket of homology modelled protein structure of GAT-1 GABA transporter.	110
5.15	3D Ribbon structure representation of docking conformation of the compound 5S2y in the hydrophobic pocket of homology modelled protein structure of GAT-1 GABA transporter.	110
5.16	Protein RMSD (Left Y-Axis) and ligand RMSD (Right Y-Axis) values in Å with time in ns (X-Axis) for the molecular dynamics simulation run for the complex of 5S2w with GAT1 GABA transporter.	112
5.17	Protein RMSF (Left side) and ligand RMSF (Right side) values in Å with time in nsec.	113
5.18	The detailed atomic interactions of ligand 5S2w with the key active amino acid residues with GABA GAT-1 transporter protein	113
5.19	Stacked bar charts of protein interactions with ligand 5S2w as monitored throughout the MD simulation.	114

Table No.	Table Captions	Page No.
1.1	Structure and mechanism of action of Anticonvulsant drugs	8
5.1	Chemical Structures and Physicochemical Properties of Compounds (3S1a-3S1i & 4S1a-4S1i)	57
5.2	Effect of the test compounds (Series 1) on s.c.PTZ induced seizures	66
5.3	Effect of the test compounds (Series 1) on pilocarpine-induced seizures	67
5.4	Effect of the test compounds (Series 1) on DMCM induced seizures	68
5.5	Effect of the test compounds (Series 1) on rota-rod performance test in mice	69
5.6	Percentage cell viability of the test compounds (Series 1) at different concentrations in neuroblastoma cell line (SH-SY5Y).	70
5.7	Effect of the test compound (4S1i) on haematological parameters of mice in 28 days repeated dose toxicity studies	72
5.8	Effect of the test compound (4S1i) on biochemical parameters of mice in 28 days repeated dose toxicity studies	72
5.9	PAMPA- BBB permeability (P_e) value for commercial drugs, Tiagabine (Standard), selected leads of Series 1	74
5.10	Details of protein-ligand interactions of tiagabine, 4S1a , 4S1b , and 4S1i	78
5.11	<i>In silico</i> drug likeliness properties of active compounds of Series 1	85
5.12	Chemical structures and physicochemical properties of compounds 5S2a-5S2y	87
5.13	Permeability analysis using PAMPA-BBB assay (Series 2)	101
5.14	Effect of the test compounds (Series 2) on s.c.PTZ induced seizures	103
5.15	Effect of the test compounds (Series 2) on DMCM induced seizures	104
5.16	Effect of the test compounds (Series 2) on rota-rod performance test in mice	104
5.17	Cell Viability of the test (Series 2) compounds at different concentrations in neuroblastoma cell line (SH-SY5Y).	105
5.18	Effect of test compound (5S2w) on hematological parameters of mice in 28 days repeated dose toxicity studies	106
5.19	Effect of test compound (5S2w) on biochemical parameters of mice in 28 days repeated dose toxicity studies	106
5.20	Details of protein-ligand interactions of tiagabine, 5S2d , 5S2w , and 5S2y	111
5.21	<i>In silico</i> drug like properties of the active compounds of Series 2	115